PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Why Is PRF Tech Stock Falling On Monday?
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
PainReform Ltd. Changes Name to PRF Technologies Ltd.
PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison
PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market
BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week
PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy
PainReform (NASDAQ:PRFX) Trading Down 1.3% – Here’s Why
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis
PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects
PainReform Provides Business Update for the Six Months Ended June 30, 2025
Nvidia enrollment sends this stock soaring 130%
PainReform/DeepSolar Accepted into NVIDIA Connect Program
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects
PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market
PainReform Provides Year-End Business Update
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
PainReform Provides Business Update for the First Quarter of 2024
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
PainReform Announces Closing of $4 Million Public Offering
PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
PainReform Provides Year-End Business Update
PainReform to Present at the Microcap Conference in Atlantic City